文献速递头颈部肿瘤放疗

基于免疫组化的缺氧-免疫预后分类器用于接受放化疗的头颈癌患者

Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation - Post-hoc analysis from a prospective imaging trial.
PubMed 文献 · Radiother Oncol · 2021-03-19

该研究基于前瞻性影像试验中39例接受根治性放化疗的头颈部鳞癌患者,分析基线肿瘤样本的缺氧标志物CAIX与肿瘤浸润淋巴细胞(TILs),并与此前[18F]FMISO PET测量相关。低CAIX和高TIL水平均为改善局部区域控制的独立因素且互不相关,联合分类器可将患者分为预后良好、中间和不良三组,2年LRC分别为73%、62%和11%(p=0.001)。

要点

  • 低CAIX和高TIL是改善LRC的独立因素,联合分类器C指数0.71。
  • 缺氧-免疫分类器将患者分为三组,2年LRC分别为73%、62%和11%。
  • 聚焦CD3+T细胞时分类器仍可分层,2年LRC分别为80%、59%和14%。

核心结论

  • 基于治疗前免疫组化的缺氧-免疫预后分类器在HNSCC患者中临床可行,但需外部验证以确定预后价值及个体化放疗应用潜力。

研究设计与样本

  • 前瞻性试验中39例接受根治性放化疗的HNSCC患者,分析基线肿瘤样本的CAIX和TILs,并与[18F]FMISO PET测量相关。
  • 采用Cox分析和一致性指数统计评估生物标志物对局部区域控制(LRC)的影响。

主要发现

  • 低CAIX(HR=0.352,95%CI 0.124-1.001,p=0.050)和高TIL水平(HR=0.308,95%CI 0.114-0.828,p=0.020)为改善LRC的独立参数,二者不相关(Spearman's ρ=0.034,p=0.846)。
  • CAIX和TIL单独及联合的Harrell's C分别为0.66和0.71。
  • 预后良好组(CAIXlow/TILhigh)、中间组(CAIXlow/TILlow或CAIXhigh/TILhigh)和不良组(CAIXhigh/TILlow)的2年LRC分别为73%、62%和11%(p=0.001)。
  • 聚焦T淋巴细胞时,有利组(CAIXlow/CD3+TILhigh)、中间组(CAIXlow/CD3+TILlow或CAIXhigh/CD3+TILhigh)和不良组(CAIXhigh/CD3+TILlow)的2年LRC分别为80%、59%和14%(p=0.001)。
  • 基线CAIX水平与放化疗第2周[18F]FMISO SUV呈正相关(ρ=0.324,p=0.050),提示基线CAIX高表达与肿瘤缺氧持续相关。

关键数值与推荐

  • 缺氧-免疫分类器基于CAIX和TIL(或CD3+TIL)的联合分层,将患者分为预后良好、中间和不良三组。
  • 2年LRC在CAIX/TIL分组中分别为73%、62%和11%(p=0.001),在CAIX/CD3+TIL分组中分别为80%、59%和14%(p=0.001)。

临床怎么用

  • 治疗前免疫组化检测CAIX和TILs可辅助预测HNSCC患者放化疗后的局部区域控制。
  • 该分类器可能有助于识别高危患者,但需外部验证后方可用于个体化放疗决策。

局限性

  • 样本量较小(39例),需外部验证确定预后价值。
  • 为前瞻性试验的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: As both tumor hypoxia and an immunosuppressing tumor microenvironment hamper the anti-tumor activity of radiotherapy in head-and-neck squamous cell carcinoma (HNSCC), we aimed to develop an immunohistochemistry-based hypoxia-immune classifier. METHODS: 39 patients receiving definitive chemoradiation for HNSCC within a prospective trial were included in this analysis. Baseline tumor samples were analyzed for the hypoxia marker carbonic anhydrase IX (CAIX) and tumor-infiltrating lymphocytes (TILs) and were correlated with [18F]-misonidazole ([18F]FMISO) PET measurements. The impact of the biomarkers on the locoregional control (LRC) was examined using Cox analyses and concordance index statistics. RESULTS: Low CAIX (HR = 0.352, 95%CI 0.124-1.001, p = 0.050) and high TIL levels (HR = 0.308, 95%CI 0.114-0.828, p = 0.020) were independent parameters for improved LRC and did not correlate with each other (Spearman's ρ = 0.034, p = 0.846). Harrell's C was 0.66 for CAIX and TIL levels alone and 0.71 for the combination. 2-year LRC was 73%, 62% and 11% for the prognostically good (CAIXlow/TILhigh), intermediate (CAIXlow/TILlow or CAIXhigh/TILhigh) and poor groups (CAIXhigh/TILlow), respectively (p = 0.001). Focusing on T lymphocytes, the hypoxia-immune classifier could still stratify between favorable (CAIXlow/CD3 + TILhigh), intermediate (CAIXlow/CD3 + TILlow or CAIXhigh/CD3 + TILhigh) and poor subgroups (CAIXhigh/CD3 + TILlow) with a 2-year LRC of 80%, 59% and 14%, respectively (p = 0.001). There was a positive correlation between baseline CAIX levels and [18F]FMISO SUV in week 2 of chemoradiation (ρ = 0.324, p = 0.050), indicating an association between higher baseline CAIX expression and tumor hypoxia persistence. CONCLUSION: We developed a clinically feasible hypoxia-immune prognostic classifier for HNSCC patients based on pre-treatment immunohistochemistry. However, external validation is required to determine the prognostic value and the potential usage for personalized radiation oncology.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Rühle A, Grosu AL, Wiedenmann N, et al. Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation - Post-hoc analysis from a prospective imaging trial. Radiother Oncol. 2021. PMID: 33753155. doi:10.1016/j.radonc.2021.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。